Third Party Event

Clinical trial strategy: ​Fine-tuning the risk-reward profile

Swiss Biotech Insights - 1/2 Day event

Trial design remains a challenge, and development the longest and most expensive component of the Biotech value creation.

The Swiss Biotech Association and Parexel invite you to Lausanne on Sept 19th for this exciting event to address major clinical trial strategy challenges. Hear from world-renowned speakers and discuss the growing complexity of trials while exploring exciting new opportunities including real world data science, adaptive clinical trial design, biomarkers and more.

Clinical trial strategy: ​Fine-tuning the risk-reward profile

The Swiss Biotech Association is launching the Swiss biotech Insight event series, designed to cover a portfolio of topics mirroring the biopharma product life cycle, namely from ideation and research to commercialization and patient benefit. The three main areas covered are discovery, development and commercialization.


Target audience Biotech, Pharmaceutical and Medtech Companies, Multinationals, SMEs and Start Ups
Organizer Swiss Biotech Association
Event language


Cost of participating CHF 50 for Swiss Biotech Association Members and CHF 100 for everyone else

Dr. Olaf Ritzeler, Director, Rare Diseases External Innovation, Sanofi
From No to Yes: What are licensing partners looking for?

Matthias Grossmann, VP, Parexel Early Phase Scientific Affairs
The fast lane to proof of concept

Dr. Andrew Galazka, MD, Senior VP, Head of Global Medical Excellence at Merck
Clinical development strategies: lessons learnt and implications for the future

Dr. Jens Wuerthner, Head of Clinical Development, ADC Therapeutics
Current challenges in oncology development

Dr. Justin Devine, Chief Medical Officer, Synexa Group Life Sciences
Using biomarkers to improve the quality of decision making in drug development

Claudia Graeve, VP, Health Advances
Real world data science and the future of clinical trial design

Pantelis Vlachos, Principal Strategic Consultant, Cytel Inc
Adaptive designs: Statistical, operational and regulatory issues

Philippe Menu, McKinsey & Company
New frontiers in pharma R&D investment: Sharing risks and rewards over product development cycle

Christian Fehr, Relationship Manager Primary Markets, and Valeria Ceccarelli, Head Primary Markets, SIX
IPO on SIX: The leadership team also goes public

Dr. Victor Cheng, Vice President, Technical, Parexel China
The China opportunity: Considerations for clinical strategy



Agora Cancer Research Centre
CHUV University Hospital, Rue du Bugnon 25A
1005 Lausanne

Recommend us
How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program